Dualitas Therapeutics secured $65 million in Series A funding to drive the development of bispecific antibodies that simultaneously engage two immune cell targets. This proximity biology-based approach aims to provide enhanced therapeutic efficacy beyond conventional monoclonal antibodies in immunology and inflammation. Investors include Eli Lilly and Chugai Pharmaceutical, signifying confidence in the platform’s potential. Dualitas's innovative modality could reshape treatment paradigms for autoimmune disorders, signaling critical momentum in bispecific antibody therapeutics.